Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of “Hold” by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a consensus rating of “Hold” from the seven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $3.25.

A number of equities research analysts have commented on the company. Weiss Ratings raised Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a research report on Monday, June 1st. Piper Sandler reiterated an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Finally, Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Focus Partners Wealth purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth $33,000. Raymond James Financial Inc. raised its holdings in shares of Inovio Pharmaceuticals by 4,396.0% in the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $41,000. Zacks Investment Management bought a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $46,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the last quarter. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ INO opened at $0.77 on Thursday. The firm’s 50-day moving average price is $1.03 and its 200-day moving average price is $1.31. Inovio Pharmaceuticals has a 1-year low of $0.56 and a 1-year high of $2.98. The firm has a market capitalization of $63.35 million, a P/E ratio of -0.53 and a beta of 1.52.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Equities research analysts forecast that Inovio Pharmaceuticals will post -0.99 EPS for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.